11. Chemokines in inflammatory bowel disease. Issue 10 (27th September 2005) Authors: Danese, S; Gasbarrini, A Journal: Journal of clinical pathology Issue: Volume 58:Issue 10(2005) Page Start: 1025 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Critical role of the CD40–CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Issue 9 (22nd February 2007) Authors: Danese, S; Scaldaferri, F; Vetrano, S; Stefanelli, T; Graziani, C; Repici, A; Ricci, R; Straface, G; Sgambato, A; Malesci, A; Fiocchi, C; Rutella, S Journal: Gut Issue: Volume 56:Issue 9(2007) Page Start: 1248 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis. Issue 11 (11th October 2004) Authors: Sturm, A; Leite, A Z A; Danese, S; Krivacic, K A; West, G A; Mohr, S; Jacobberger, J W; Fiocchi, C Journal: Gut Issue: Volume 53:Issue 11(2004) Page Start: 1624 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open. (16th January 2018) Authors: Sands, B E; Moss, A C; Armuzzi, A; Marshall, J K; Lindsay, J O; Sandborn, W J; Danese, S; Tsilkos, K; Lawendy, N; Zhang, H; Friedman, G S; Chan, G; Krichbaum, D W; Su, C Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S049 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. DOP05 Target engagement and pharmacodynamic biomarker analysis following treatment with the oral gut-targeted HIF-1α stabilizer GB004 in a Phase 1b trial in Active Ulcerative Colitis. (27th May 2021) Authors: Sandborn, W; Ding, Z; Osterhout, R; Feagan, B; Danese, S; Jucov, A; Bhandari, B R; Raghupathi, K; Olson, A; Van Biene, C; Ford, J; Aranda, R; Levesque, B G; Bruey, J M Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S043 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. DOP24 Patient-reported health-related quality-of-life outcomes with vedolizumab vs. adalimumab treatment of ulcerative colitis: Results of the VARSITY trial. (15th January 2020) Authors: Loftus, E V; Schreiber, S W; Danese, S; Peyrin-Biroulet, L; Colombel, J F; Sands, B E; Wang, S; Chen, J; Lirio, R A Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S063 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. DOP36 Non-invasive assessment of postoperative disease recurrence in Crohn's Disease: A multicenter, prospective cohort study. (27th May 2021) Authors: Furfaro, F; Zilli, A; Craviotto, V; Aratari, A; Bezzio, C; Gilardi, D; D'Amico, F; Saibeni, S; Papi, C; Peyrin-Biroulet, L; Fiorino, G; Danese, S; Allocca, M Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S074 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study. (30th January 2023) Authors: Danese, S; Abreu, M T; Wolf, D C; Canavan, J B; Jain, A; Wu, H; Petersen, A; Charles, L; Panaccione, R; Afzali, A Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. DOP37 Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies. (21st January 2022) Authors: Schreiber, S; Loftus, E V; Maaser, C; Danese, S; Rudolph, C; Jongen, R; De Haas, A; Oortwijn, A; Vermeire, S Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i085 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. DOP38 Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1. (21st January 2022) Authors: Vermeire, S; Colombel, J F; Takeuchi, K; Gao, X; Panaccione, R; Danese, S; Dubinsky, M; Schreiber, S; Ilo, D; Finney-Hayward, T; Zhou, W; Phillips, C; Yao, X; Zhou, Q; Loftus, E Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗